Ting Yan1, Shuang-Ling Li1, Hai-Li Ou2, Sai-Nan Zhu3, Lei Huang2, Dong-Xin Wang4. 1. Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China. 2. Department of Clinical Laboratory, Peking University First Hospital, Beijing, China. 3. Department of Biostatistics, Peking University First Hospital, Beijing, China. 4. Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China. wangdongxin@hotmail.com.
Abstract
BACKGROUND: Intra-abdominal candidiasis (IAC) is the predominant type of invasive candidiasis with high mortality in surgical intensive care patients. The purpose of this study was to investigate the impact of appropriate source control and antifungal therapy on the outcomes of critically ill surgical patients with IAC. METHODS: This was a retrospective single-center cohort study. Adult surgical patients who were admitted to the intensive care unit and diagnosed with IAC from January 1, 2003, to December 31, 2016, were enrolled. The patients' data including risk factors of IAC, infection-related information, antifungal treatment and 30-day outcomes were collected. The primary endpoint was 30-day mortality. A COX proportional hazards model was used to analyze the association between appropriate treatment and 30-day survival. RESULTS: A total of 82 patients were included in the analysis. Of these, 45 (54.9%) were complicated with septic shock at IAC diagnosis. Types of IAC included peritonitis (61.0%), intra-abdominal abscesses (23.2%) and biliary tract infections (15.9%). Of the included patients, 53 (64.6%) received appropriate source control and 44 (53.7%) appropriate antifungal therapy. Compared with patients with neither of these treatments, appropriate source control (HR 0.08, 95% CI 0.02-0.30; P < 0.001), appropriate antifungal therapy (HR 0.14, 95% CI 0.04-0.55; P = 0.005), and a combination of these treatments (HR 0.02, 95% CI 0.00-0.08; P < 0.001) were associated with reduced risk of death within 30 days after IAC diagnosis. CONCLUSION: For critically ill surgical patients with IAC, both appropriate source control and appropriate antifungal therapy were associated with reduced risk of 30-day mortality, and the protective effects of the two appropriate treatments were additive.
BACKGROUND:Intra-abdominal candidiasis (IAC) is the predominant type of invasive candidiasis with high mortality in surgical intensive care patients. The purpose of this study was to investigate the impact of appropriate source control and antifungal therapy on the outcomes of critically ill surgical patients with IAC. METHODS: This was a retrospective single-center cohort study. Adult surgical patients who were admitted to the intensive care unit and diagnosed with IAC from January 1, 2003, to December 31, 2016, were enrolled. The patients' data including risk factors of IAC, infection-related information, antifungal treatment and 30-day outcomes were collected. The primary endpoint was 30-day mortality. A COX proportional hazards model was used to analyze the association between appropriate treatment and 30-day survival. RESULTS: A total of 82 patients were included in the analysis. Of these, 45 (54.9%) were complicated with septic shock at IAC diagnosis. Types of IAC included peritonitis (61.0%), intra-abdominal abscesses (23.2%) and biliary tract infections (15.9%). Of the included patients, 53 (64.6%) received appropriate source control and 44 (53.7%) appropriate antifungal therapy. Compared with patients with neither of these treatments, appropriate source control (HR 0.08, 95% CI 0.02-0.30; P < 0.001), appropriate antifungal therapy (HR 0.14, 95% CI 0.04-0.55; P = 0.005), and a combination of these treatments (HR 0.02, 95% CI 0.00-0.08; P < 0.001) were associated with reduced risk of death within 30 days after IAC diagnosis. CONCLUSION: For critically ill surgical patients with IAC, both appropriate source control and appropriate antifungal therapy were associated with reduced risk of 30-day mortality, and the protective effects of the two appropriate treatments were additive.
Authors: John E Mazuski; Jeffrey M Tessier; Addison K May; Robert G Sawyer; Evan P Nadler; Matthew R Rosengart; Phillip K Chang; Patrick J O'Neill; Kevin P Mollen; Jared M Huston; Jose J Diaz; Jose M Prince Journal: Surg Infect (Larchmt) Date: 2017-01 Impact factor: 2.150
Authors: Joseph S Solomkin; Ross L Ristagno; Anita F Das; John B Cone; Samuel E Wilson; Ori D Rotstein; Brian S Murphy; Kimberley S Severin; Jon B Bruss Journal: Clin Infect Dis Date: 2013-03-05 Impact factor: 9.079
Authors: Luis Ostrosky-Zeichner; Bart Jan Kullberg; Eric J Bow; Susan Hadley; Cristóbal León; Marcio Nucci; Thomas F Patterson; John R Perfect Journal: Med Mycol Date: 2010-09-06 Impact factor: 4.076
Authors: Tobias M Bingold; Rolf Lefering; Kai Zacharowski; Patrick Meybohm; Christian Waydhas; Peter Rosenberger; Bertram Scheller Journal: PLoS One Date: 2015-08-04 Impact factor: 3.240